Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 7/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.47 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.46 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22972009 | 0.94 | DDR2 (0.56) | USP2KDRBRAFMAPK14TNNI3K | |
| SCHEMBL22972145 | 0.82 | DDR2 (0.54) | KDRBRAFMAPK14TNNI3KDDR2 | |
| SCHEMBL30050285 | 0.82 | DDR2 (0.54) | KDRBRAFMAPK14TNNI3KDDR2 | |
| SCHEMBL30049303 | 0.82 | DDR2 (0.54) | KDRDDR2PDGFRAAXLMET | |
| SCHEMBL29318681 | 0.82 | DDR2 (0.54) | KDRDDR2PDGFRAAXLMET | |
| SCHEMBL22972012 | 0.81 | SMN1; SMN2 (0.49) | KDRBRAFMAPK14TNNI3KAXL | |
| SCHEMBL24724269 | 0.79 | MEN1 (0.58) | KDRBRAFMAPK14TNNI3KPDGFRA | |
| SCHEMBL29317823 | 0.79 | DDR2 (0.54) | BRAFDDR2PDGFRAHTTFGFR2 | |
| SCHEMBL24724242 | 0.79 | KDR (0.50) | KDRBRAFMAPK14TNNI3KPDGFRA | |
| SCHEMBL22972144 | 0.77 | AKR1C3 (0.56) | KDRBRAFMAPK14TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, CPT1A, OAT | USP2 3182/4885KDR 4885/4885BRAF 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.